1. Home
  2. WLKP vs ANNX Comparison

WLKP vs ANNX Comparison

Compare WLKP & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Westlake Chemical Partners LP

WLKP

Westlake Chemical Partners LP

N/A

Current Price

$21.22

Market Cap

743.7M

Sector

Industrials

ML Signal

N/A

Logo Annexon Inc.

ANNX

Annexon Inc.

N/A

Current Price

$4.21

Market Cap

726.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
WLKP
ANNX
Founded
2014
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
743.7M
726.1M
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
WLKP
ANNX
Price
$21.22
$4.21
Analyst Decision
Buy
Analyst Count
0
10
Target Price
N/A
★ $17.00
AVG Volume (30 Days)
15.1K
★ 3.6M
Earning Date
11-04-2026
11-17-2026
Dividend Yield
★ 8.83%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
★ $1,166,695,000.00
N/A
Revenue This Year
$16.25
N/A
Revenue Next Year
$5.23
N/A
P/E Ratio
$15.30
★ N/A
Revenue Growth
★ 2.71
N/A
52 Week Low
$17.75
$2.54
52 Week High
$23.88
$7.18

Technical Indicators

Market Signals
Indicator
WLKP
ANNX
Relative Strength Index (RSI) 47.81 54.86
Support Level $20.84 $3.71
Resistance Level $22.61 $4.37
Average True Range (ATR) 0.42 0.26
MACD 0.05 0.06
Stochastic Oscillator 34.45 65.34

Price Performance

Historical Comparison
WLKP
ANNX

About WLKP Westlake Chemical Partners LP

Westlake Chemical Partners LP is a part of the chemical industry in the United States. Its operations are conducted through OpCo, it acquires and develops ethylene production facilities, which convert ethane into ethylene. OpCo sells ethylene and its co-products, such as propylene, crude butadiene, pyrolysis gasoline, and hydrogen, to Westlake and other customers located in the United States. Its assets include three ethylene production facilities in Calvert City, Kentucky, and Lake Charles, Louisiana.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: